Drugs / Nabi-IGIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00538915 | Sep 2007 → Jul 2009 | immunodeficiency disease | ADMA Biologics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nabi-IGIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00538915 ↗ |
| Known as | Immune Globulin Intravenous (Human), 10% | “Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution” NCT00538915 ↗ |
| Modality | Protein / enzyme biologic | “10% protein concentration of immunoglobulin G” NCT00538915 ↗ |
| Route | Intravenous | “Serum IgG PK of IVIG following intravenous infusion was characterized” PMID 42218742 ↗ Jun 2026 |